-

Cerus Corporation Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriter’s Option to Purchase Additional Shares

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today the closing of a registered underwritten public offering of its common stock, which included the sale of additional shares of common stock upon full exercise of the underwriter’s option to purchase additional shares. Total proceeds for the offering were $63.3 million, before deducting estimated offering expenses payable by Cerus.

BTIG, LLC acted as sole book-running manager for the offering.

A shelf registration statement on Form S-3 (File No. 333-219727) relating to the shares of common stock described above was previously filed by Cerus with the Securities and Exchange Commission ("SEC") and declared effective on January 8, 2018. You should read the prospectus in the registration statement and related final prospectus supplement that Cerus has filed with the SEC for complete information about Cerus and this offering. A final prospectus supplement and accompanying prospectus relating to the offering is available on the SEC's website located at http://www.sec.gov. Alternatively, copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting BTIG, LLC at 65 East 55th Street, New York, NY, 10022, by email at equitycapitalmarkets@btig.com or by telephone at (212) 593-7555.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply. Based in Concord, California, Cerus develops and markets the INTERCEPT Blood System. Cerus currently markets and sells the INTERCEPT Blood System in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world.

Contacts

Tim Lee – Investor Relations Director
Cerus Corporation
925-288-6137

Cerus Corporation

NASDAQ:CERS

Release Versions

Contacts

Tim Lee – Investor Relations Director
Cerus Corporation
925-288-6137

More News From Cerus Corporation

Cerus Corporation Announces Record Results for Third Quarter 2025 and Raises Full Year 2025 Product Revenue Guidance

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today financial results for the third quarter ended September 30, 2025, and provided a business update. “We continue to make great strides in improving the safety and availability of transfused blood components around the globe and the record quarterly product revenue results reflect that progress. Product revenue growth was driven by strong global commercial execution and growing awareness of the benefits conferred by...

Cerus Corporation Announces Abstracts and Industry Workshop on IFC at the 2025 AABB Annual Meeting

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that it will host an industry workshop on the benefits of Pathogen Reduced Cryoprecipitated Fibrinogen Complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, at the 2025 Association for the Advancement of Blood and Biotherapies (AABB) Annual Meeting, taking place in San Diego, California from October 25 through October 28. The AABB Annual Meeting attracts healthcare professionals, scientists, and...

Cerus Corporation to Release Third Quarter 2025 Financial Results on November 6, 2025

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2025 financial results will be released on Thursday, November 6, 2025, after the close of the stock market. The Company will host a conference call and webcast at 4:30 P.M. ET, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast and view the presentation slides, please visit the Investor Rela...
Back to Newsroom